Lear (LEA) Earns Daily News Impact Rating of 0.09

Leslie Hanson
January 13, 2018

Spitfire Capital Llc sold 12,400 shares as the company's stock rose 0.77% with the market. Geode Cap Mgmt Ltd Company holds 831,450 shares.

Developed by James O'Shaughnessy, the Value Composite score uses six valuation ratios. The stock increased 0.93% or $1.51 during the last trading session, reaching $164.51. About 127,584 shares traded. Lear Corporation (NYSE:LEA) has risen 28.33% since January 10, 2017 and is uptrending. It has outperformed by 11.63% the S&P500. TPIV's SI was 67,500 shares in January as released by FINRA. Its up 15.06% from 242,400 shares previously. (NASDAQ:INTU) shares were sold by Williams R Neil. The SI to Tapimmune Incorporated's float is 0.81%. The stock increased 2.29% or $4.23 during the last trading session, reaching $189.14. About 326,393 shares traded or 140.44% up from the average. LGI Homes, Inc. (NASDAQ:LGIH) has risen 30.68% since January 10, 2017 and is uptrending. It has underperformed by 0.92% the S&P500. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Therefore 75% are positive. The stock presently has an average rating of Buy and a consensus price target of $179.50. The firm has "Buy" rating by Raymond James given on Saturday, August 22. (NYSE:TIME) has "Hold" rating given on Friday, November 17 by Gabelli. The stock of TRACON Pharmaceuticals, Inc. (NASDAQ:INTU) has "Buy" rating given on Monday, May 23 by Goldman Sachs.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The stock has a market cap of $12,780.00, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 1.50 and a beta of 1.44. The Company's lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It now has negative earnings. It specializes in the development of immunotherapies targeting womenÂ's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers.

Exane Derivatives increased Ss And C Techn. (NASDAQ:SSNC) stake by 44,976 shares to 45,454 valued at $1.82 million in 2017Q3. It also upped Cl A stake by 36,680 shares and now owns 106,751 shares. West Pharmaceutical Svsc Inc (NYSE:WST) was raised too. The stock of Lear Corporation (NYSE:LEA) has "Outperform" rating given on Thursday, October 26 by RBC Capital Markets. Therefore 50% are positive. The VC1 of Lear Corporation (NYSE:LEA) is 27. The rating was maintained by KeyBanc Capital Markets with "Buy" on Friday, October 13. The firm has "Buy" rating given on Thursday, April 28 by Argus Research. Finally, Bank of America Corporation lowered Lear Corporation from a "neutral" rating to an "underperform" rating and lowered their price objective for the company from $145.00 to $115.00 in a research note on Wednesday, November 9th. Parametric Assocs Limited Liability stated it has 426,339 shares or 0.08% of all its holdings. Barclays Capital has "Equal-Weight" rating and $175 target. RBC Capital Markets upgraded the stock to "Outperform" rating in Thursday, October 26 report. The firm has "Hold" rating by RBC Capital Markets given on Monday, October 16. The firm has "Sector Perform" rating given on Friday, February 24 by RBC Capital Markets. Bank of America downgraded Lear Corporation (NYSE:LEA) on Tuesday, June 21 to "Neutral" rating. During the same quarter previous year, the firm earned $3.19 EPS. LEA's profit will be $288.47 million for 10.83 P/E if the $4.27 EPS becomes a reality. The auto parts company reported $3.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.80 by $0.16.

Since September 18, 2017, it had 0 insider buys, and 3 selling transactions for $1.60 million activity. 19,757 shares valued at $4.85 million were sold by Smith Gregory D on Monday, July 31. The insider STANSBURY HENRY TAYLOE sold 15,415 shares worth $2.18M. 2,411 shares were sold by STEPHENS MEL, worth $416,802.

Investors sentiment decreased to 0.92 in Q3 2017. Its up 0.08, from 0.84 in 2017Q2.

Zacks Investment Research upgraded shares of Lear (NYSE:LEA) from a hold rating to a buy rating in a report published on Tuesday. 61 funds opened positions while 135 raised stakes. Blair William & Il accumulated 0.01% or 7,991 shares.

Lear (NYSE:LEA) last issued its earnings results on Wednesday, October 25th. Midas Management Corporation has invested 0.64% in Lear Corporation (NYSE:LEA). Brandywine Inv Ltd Liability Corp holds 0.07% of its portfolio in Lear Corporation (NYSE:LEA) for 62,564 shares. Camarda Fincl Advsrs Ltd Co invested in 12,478 shares or 2.32% of the stock. They expect $2.87 earnings per share, up 16.19% or $0.40 from last year's $2.47 per share. Bb&T Corp holds 47,843 shares. Interest Gru Inc holds 0.01% or 11,995 shares in its portfolio. Chevy Chase Tru Holdg holds 0% or 1,542 shares in its portfolio. Guggenheim Ltd, Illinois-based fund reported 104,082 shares. 5,143 were reported by Gsa Llp. Cornerstone Capital Management Holdg Limited Liability Company reported 0.07% of its portfolio in Lear Corporation (NYSE:LEA).

Other reports by Iphone Fresh

Discuss This Article